Warning Letters

October 7, 2024

In case you haven’t heard…

The FDA has issued warning letters to two Chinese firms regarding data quality and integrity concerns. The agency is particularly concerned about the reliability of data used in medical device submissions. As a result, the FDA will not authorize submissions where the data is necessary for approval. Additionally, the FDA is reviewing past submissions for potential impact.

 

The key takeaways are:

Device firms are ultimately responsible for the integrity of all data submitted to the FDA, even if it’s generated by a third-party testing lab.

FDA does not intend to authorize submissions where the data [from these two sites] are necessary for the FDA to make a marketing authorization decision.

 

Please share this information with any potentially impacted companies.

 

Primary Source:

FDA Issues Warning Letters to Two Chinese Firms Regarding Data Quality and Integrity Concerns, Violative Lab Practices | FDA

 

Links found in the article:

 

Questions?

Skip to content